Studies on prostate cancer, hematological malignancies, renal cell carcinoma, and NSCLC have associated low serum CD80 expression with progression-free survival while high levels are associated with enhanced invasiveness and poor prognosis (115–118). This evidence concerns the gene CD80 and hematologic disorder.